Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maria Fernanda Fortiz"'
Autor:
Hannah Kinoshita, Kenneth R. Cooke, Melanie Grant, Maja Stanojevic, C. Russell Cruz, Michael Keller, Maria Fernanda Fortiz, Fahmida Hoq, Haili Lang, A. John Barrett, Hua Liang, Jay Tanna, Nan Zhang, Abeer Shibli, Anushree Datar, Kenneth Fulton, Divyesh Kukadiya, Anqing Zhang, Kirsten M. Williams, Hema Dave, Jeffrey S. Dome, David Jacobsohn, Patrick J. Hanley, Richard J. Jones, Catherine M. Bollard
Publikováno v:
Blood advances. 6(8)
Patients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies, with an expected 1-year overall survival (OS) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e0bed35d7af5d7e4df459ae64a317df
https://pubmed.ncbi.nlm.nih.gov/35244681
https://pubmed.ncbi.nlm.nih.gov/35244681
Autor:
Fahmida Hoq, Christopher A. Lazarski, Anushree Datar, Jennifer Wang, Melanie Grant, Jay Tanna, Nan Zhang, Adriana Pitino, Eugene Hwang, Catherine M. Bollard, Patrick J. Hanley, Brian R. Rood, Maria Fernanda Fortiz, Madeline Terpilowski, Emily K. Reynolds, Roger J. Packer, Lindsay Kilburn, Haili Lang
Publikováno v:
Neuro Oncol
BACKGROUND Patients with relapsed CNS malignancies or DIPG face terrible prognoses. We hypothesized that T cells specific for 3 tumor-associated antigens (TAA), WT1, PRAME and survivin, would be safe and elicit anti-tumor immunity. METHODS Patients (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e754c97f87fd3e7e6506f05dc661f7b2
https://europepmc.org/articles/PMC7650401/
https://europepmc.org/articles/PMC7650401/
Autor:
Fahmida Hoq, Jeffrey S. Dome, Emily K. Reynolds, Madeline Terpilowski, Holly J. Meany, Haili Lang, Robert Ulrey, Maja Stanojevic, Amy B. Hont, Conrad Russell Y. Cruz, Maria Fernanda Fortiz, Patrick J. Hanley, Catherine M. Bollard
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Patients with relapsed or refractory Wilms tumor (WT) have poor prognoses with limited treatment options.1–3 Immunotherapy offers a promising alternative for targeted therapy but has been limited by immune evasion tactics.4–6 Adoptive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f022d0a094070cb42002ea3ae00c2148
https://doaj.org/article/45fdbbf05d7e4f91b23afcbf5c345df4
https://doaj.org/article/45fdbbf05d7e4f91b23afcbf5c345df4
Autor:
Catherine M. Bollard, David A. Jacobsohn, Kenneth R. Cooke, Nan Zhang, Anushree Datar, Hema Dave, Jeffrey S. Dome, Maja Stanojevic, Kirsten M. Williams, Maria Fernanda Fortiz, Michael D. Keller, Hua Liang, Conrad Russell Y. Cruz, Jay Tanna, Fahmida Hoq, Melanie Grant, Hannah Kinoshita, Patrick J. Hanley, Richard J. Jones, Abeer Shibli, John Barrett, Haili Lang
Publikováno v:
Blood. 138:2828-2828
Background: Patients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies with an expected 1-year overall survival (OS) of Methods: Lymphocytes obtained
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ce6fee4ad6235771006b5e378e32f34
https://doi.org/10.1182/blood-2021-153207
https://doi.org/10.1182/blood-2021-153207
Autor:
Jeffrey S. Dome, Payal Banerjee, Yunfei Wang, Maria Fernanda Fortiz, Holly J. Meany, C. Russell Cruz, Amy B. Hont, Fahmida Hoq, Robert Ulrey, Shuroug Albihani, Barbara O’Brien, Devin Saunders, Patrick J. Hanley, Haili Lang, Catherine M. Bollard, Maja Stanojevic, Ryo Hanajiri, Sam Darko, Karuna Panchapakesan, Anushree Datar
PURPOSE Tumor-associated antigen cytotoxic T cells (TAA-Ts) represent a new, potentially effective and nontoxic therapeutic approach for patients with relapsed or refractory solid tumors. In this first-in-human trial, we investigated the safety of ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4450fc042134532c3b0a9f8f98a46c2a
https://europepmc.org/articles/PMC6804838/
https://europepmc.org/articles/PMC6804838/
Autor:
Melanie Grant, Maria Fernanda Fortiz, Lu Wang, Haili Lang, Anushree Datar, Emily Reynolds, Madeline Terpilowski, Chris Lazarski, Jay Tanna, Adriana Pitino, Nan Zhang, Fahmida Hoq, Patrick Hanley, Lindsay Kilburn, Roger Packer, Brian Rood, Catherine Bollard, Eugene Hwang
Publikováno v:
Neuro-Oncology
BACKGROUND Patients with relapsed CNS malignancies or DIPG face terrible prognoses. We hypothesized that T cells specific for 3 tumor-associated antigens (TAA), WT1, PRAME and survivin, would be safe and elicit anti-tumor immunity. METHODS Patients (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f347cdae4841f8559c6a9a9bc978f77b
http://europepmc.org/articles/PMC7715090
http://europepmc.org/articles/PMC7715090
Autor:
Shuroug Albihaini, Maja Stanojevic, Catherine M. Bollard, Robert Ulrey, Maria Fernanda Fortiz, Patrick J. Hanley, Fahmida Hoq, Haili Lang, C. Russell Cruz, Barbara O’Brien, Devin Saunders, Amy Houghtelin, Holly J. Meany
Publikováno v:
Journal of Clinical Oncology. 36:3042-3042
3042Background: Patients with solid tumors refractory to standard therapies have poor prognoses, and most salvage therapies are toxic and ineffective. Antigen-specific T cell therapies offer a prom...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc03a54d0dd1f87e479155a0f9a10b91
https://doi.org/10.1200/jco.2018.36.15_suppl.3042
https://doi.org/10.1200/jco.2018.36.15_suppl.3042